S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Workday: Another AI Winner Melting-Up 
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
New "Mined in America" Lithium Opportunities? (Ad)
Taiwan Semiconductor Well Positioned for the AI Rush
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Workday: Another AI Winner Melting-Up 
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
New "Mined in America" Lithium Opportunities? (Ad)
Taiwan Semiconductor Well Positioned for the AI Rush
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Workday: Another AI Winner Melting-Up 
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
New "Mined in America" Lithium Opportunities? (Ad)
Taiwan Semiconductor Well Positioned for the AI Rush
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Workday: Another AI Winner Melting-Up 
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
New "Mined in America" Lithium Opportunities? (Ad)
Taiwan Semiconductor Well Positioned for the AI Rush
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
NASDAQ:RXRX

Recursion Pharmaceuticals (RXRX) Stock Forecast, Price & News

$8.93
+0.27 (+3.12%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$8.43
$9.04
50-Day Range
$4.56
$9.25
52-Week Range
$4.54
$14.18
Volume
1.75 million shs
Average Volume
2.97 million shs
Market Capitalization
$1.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.40

Recursion Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
38.9% Upside
$12.40 Price Target
Short Interest
Bearish
17.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.05mentions of Recursion Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.26 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.41) to ($1.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

644th out of 1,009 stocks

Biological Products, Except Diagnostic Industry

99th out of 167 stocks


RXRX stock logo

About Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Receive RXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RXRX Stock News Headlines

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.8%
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Altitude Lab Relocates to Gateway’s BioHive Hub
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 6.8%
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
8-K: RECURSION PHARMACEUTICALS, INC.
Expert Ratings for Recursion Pharmaceuticals
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 6.5%
See More Headlines
Receive RXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RXRX Company Calendar

Last Earnings
5/08/2023
Today
5/29/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RXRX
Employees
400
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.40
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+38.9%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-239,480,000.00
Net Margins
-533.45%
Pretax Margin
-533.45%

Debt

Sales & Book Value

Annual Sales
$39.84 million
Book Value
$2.54 per share

Miscellaneous

Free Float
149,559,000
Market Cap
$1.72 billion
Optionable
Not Optionable
Beta
-0.43

Key Executives

  • Dr. Christopher C. Gibson Ph.D. (Age 40)
    Co-Founder, CEO & Director
    Comp: $673.59k
  • Ms. Tina Marriott LarsonMs. Tina Marriott Larson (Age 48)
    COO & Pres
    Comp: $595.95k
  • Dr. Blake C. Borgeson Ph.D. (Age 41)
    Co-Founder & Director
    Comp: $30k
  • Dr. Michael Secora Ph.D. (Age 40)
    Chief Financial Officer
    Comp: $510.34k
  • Dr. Shafique Virani M.D. (Age 52)
    Interim Chief Medical Officer & Chief Bus. Officer
    Comp: $688.17k
  • Kevin Leggat
    VP of Fin. & Accounting
  • Mr. Benjamin Mabey M.S. (Age 40)
    Chief Technology Officer
  • Mr. Jared Allenbach
    Sr. Director of Investor Relations
  • Ms. Louisa Daniels J.D. (Age 65)
    M.B.A., Chief Legal Officer & Gen. Counsel
  • Mr. Ryan Kelly
    Chief Communications Officer













RXRX Stock - Frequently Asked Questions

Should I buy or sell Recursion Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Recursion Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RXRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXRX, but not buy additional shares or sell existing shares.
View RXRX analyst ratings
or view top-rated stocks.

What is Recursion Pharmaceuticals' stock price forecast for 2023?

5 Wall Street analysts have issued 12 month target prices for Recursion Pharmaceuticals' shares. Their RXRX share price forecasts range from $8.00 to $20.00. On average, they anticipate the company's stock price to reach $12.40 in the next twelve months. This suggests a possible upside of 38.9% from the stock's current price.
View analysts price targets for RXRX
or view top-rated stocks among Wall Street analysts.

How have RXRX shares performed in 2023?

Recursion Pharmaceuticals' stock was trading at $7.71 on January 1st, 2023. Since then, RXRX stock has increased by 15.8% and is now trading at $8.93.
View the best growth stocks for 2023 here
.

When is Recursion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our RXRX earnings forecast
.

How were Recursion Pharmaceuticals' earnings last quarter?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) posted its quarterly earnings results on Monday, May, 8th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.01. The company had revenue of $12.13 million for the quarter, compared to analysts' expectations of $15.93 million. Recursion Pharmaceuticals had a negative trailing twelve-month return on equity of 57.15% and a negative net margin of 533.45%.

When did Recursion Pharmaceuticals IPO?

(RXRX) raised $306 million in an initial public offering on Friday, April 16th 2021. The company issued 18,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO.

What is Recursion Pharmaceuticals' stock symbol?

Recursion Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXRX."

Who are Recursion Pharmaceuticals' major shareholders?

Recursion Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (13.14%), BlackRock Inc. (5.56%), State Street Corp (3.33%), FMR LLC (2.49%), ARK Investment Management LLC (1.87%) and Platinum Investment Management Ltd. (1.45%). Insiders that own company stock include Blake Borgeson, Christopher Gibson, Dean Y Li, Mubadala Investment Co Pjsc, Shafique Virani and Tina Marriott Larson.
View institutional ownership trends
.

How do I buy shares of Recursion Pharmaceuticals?

Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Recursion Pharmaceuticals' stock price today?

One share of RXRX stock can currently be purchased for approximately $8.93.

How much money does Recursion Pharmaceuticals make?

Recursion Pharmaceuticals (NASDAQ:RXRX) has a market capitalization of $1.72 billion and generates $39.84 million in revenue each year. The company earns $-239,480,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Recursion Pharmaceuticals have?

The company employs 400 workers across the globe.

How can I contact Recursion Pharmaceuticals?

Recursion Pharmaceuticals' mailing address is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. The official website for the company is www.recursion.com. The company can be reached via phone at 385-269-0203, via email at investorrelations@recursion.com, or via fax at 801-821-2872.

This page (NASDAQ:RXRX) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -